

17 February 2020

ASX Announcement

Investor briefing notification

MELBOURNE Australia, 17 February 2020: AdAlta Limited (ASX: 1AD), the biotechnology company using its i-body technology to develop drug candidates against hard to drug targets, will hold an investor briefing in Melbourne on 3 March 2020.

CEO of AdAlta, Dr Tim Oldham commented, “The investor briefing is an opportunity for AdAlta to update investors after my first 120 days as CEO on our progress, vision and plans for the company over the medium term. I am excited about the opportunities before us and look forward to sharing some of these with investors. We look forward to seeing all those who can attend and will release presentation materials before and video summaries after the event for those who are unable to attend in person.”

The AdAlta team will discuss:

- AdAlta’s strategic vision and goals
- Progress and strategy for lead fibrosis candidate, AD-214
 - Latest preclinical data
 - Development and use of a PET tracer version
 - Phase 1 clinical strategy
- Continuous improvement initiatives: Next generation i-body platform and manufacturing
- Pipeline expansion opportunities
- Plan to undertake staged growth

Those investors interested in attending in person are invited to register interest with Lauren Byrne via lauren.byrne@irdepartment.com.au by 25 February 2020.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
February 2020

Notes to Editors About AdAlta

AdAlta Limited is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, capable of uniquely interacting with previously difficult to access targets such as G-protein coupled receptors and ion channels that are implicated in many serious diseases.

AdAlta is currently preparing for its Phase 1 clinical studies for its lead i-body candidate, AD-214. The clinical program is expected to commence in mid-2020 following clinical trial design finalisation and completion of a pre-clinical study to inform dose levels. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. The Company is also in collaborative partnerships to advance the development of its i-body platform. It has an agreement with UK-based research organisation, Excellerate Bioscience to collaborate on an undisclosed target of commercial interest and an agreement with GE Healthcare for diagnostic imaging agents against several drug targets, including Granzyme B.

AdAlta plans to continue further drug discovery and development directed towards other drug targets and diseases.

Further information can be found at: www.adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au